Mirtazapine
- 1 April 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 17, 34S-39S
- https://doi.org/10.1097/00004714-199704001-00005
Abstract
Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. In addition, mirtazapine was found to be equally effective as clomipramine in the treatment of severely depressed, hospitalized patients. The overall improvement with mirtazapine is seen after 1 week of treatment and is sustained throughout the treatment period. It is paralleled by an improvement in depressed mood, the core symptom of depressive illness. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.Keywords
This publication has 22 references indexed in Scilit:
- A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depressionJournal of Psychopharmacology, 1996
- A double‐blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patientsActa Psychiatrica Scandinavica, 1996
- The effects of mirtazapine on central noradrenergic and serotonergic neurotransmissionInternational Clinical Psychopharmacology, 1995
- Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patientsHuman Psychopharmacology: Clinical and Experimental, 1995
- A double-blind placebo-controlled study of Org 3770 in depressed outpatientsJournal of Affective Disorders, 1995
- Clinically relevant effect sizes in depressionEuropean Neuropsychopharmacology, 1994
- Double-blind study of mirtazapine and placebo in hospitalized patients with major depressionEuropean Neuropsychopharmacology, 1994
- The α2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivoEuropean Journal of Pharmacology, 1994
- A general parametric approach to the meta‐analysis of randomized clinical trialsStatistics in Medicine, 1991
- Effect of the antidepressant Org 3770 on human sleepEuropean Journal of Clinical Pharmacology, 1990